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Transplant of cells which make biologic agents that can modulate the sensory and motor responses after spinal cord injury (SCI)
would be useful to treat pain and paralysis. To address this need for clinically useful human cells, a unique neuronal cell line
that synthesizes and secretes/releases the neurotransmitter serotonin (5HT) was isolated. Hind paw tactile allodynia and thermal
hyperalgesia induced by severe contusive SCI were potently reversed after lumbar subarachnoid transplant of diﬀerentiated cells,
buthad noeﬀect onopenﬁeldmotorscores,stridelength,footrotation,baseofsupport,orgridwalkfootfallerrorsassociatedwith
the SCI. The sensory eﬀects appeared 1 week after transplant and did not diminish during the 8-week course of the experiment
when grafts were placed 2 weeks after SCI. Manygrafted cells were still present and synthesizing5HT at the end of the study. These
data suggest that the human neuronal serotonergic hNT2.19 cells can be used as a biologic minipump for receiving SCI-related
neuropathic pain, but likely requires intraspinal grafts for motor recovery.
1.Introduction
Current understanding of central and supraspinal [1]m e c h -
anisms for the induction and maintenance of chronic pain
after SCI suggests a major role for the hypofunction of
serotonergic (5HT) inhibitory systems [2–4]. SCI also leads
to the loss of descending serotonergic excitatory inputs
caudal to the lesion site and altered neurotransmitter levels
within the ventral horn α-motoneurons, which contributes
to motor dysfunction [5, 6]. Multiple animal studies have
used a 5HT rat cell line [5, 7–9] or 5HT raphe transplants
[10, 11] as a means to ameliorate some of the impairments
associated with spinal injury. Supplemental cell therapy after
spinal injury can create a spinal environment conducive to
the amelioration of local damage and promotion of a regen-
erative response in multiple axonal populations, including
descending spinal serotonin ﬁbers [12]o rr e v e r s en e u r o -
pathic pain by reversing hyperexcitability in the dorsal horn
[9]. Thus, a human 5HT neuronal cell line that can restore
the function(s) of a damaged nervous system, and be genet-
ically manipulated, stored, and expanded, would potentially
be extremely useful for clinical applications.
A number of animal models have been developed for
SCI to producereliable and consistent conditions mimicking
human neuropathic pain. These include photochemically
induced ischemia [13], hemisection of the spinal cord [14,
15], and excitotoxic lesions using intraspinal injections of
excitatory amino acid agonists [16–18]. In addition, the se-
vere contusive SCI model with a weight drop device (NYU
impact injury) has been used to examine both pain [19, 20]
and motor dysfunction [21–23] in a variety of studies. These
models induce changes in intraspinal biochemistry through2 Neurology Research International
the loss, among other mechanisms, of modulation by the
5HT-releasing interneurons in the cord and a loss of
supraspinal control of voluntary locomotor activity. These
mechanisms are further supported by the studiesof denerva-
tion supersensitivity to 5-HT following SCI, which corrob-
orate behavioral studies showing the eﬀectiveness of 5-
HT in reducing allodynia and hyperalgesia after SCI [4]
and improvement of motor function with 5HT1A receptor
agonists [24]. Previous studies of locomotor recovery after
SCI have used intraspinal transplants of hNT2.19 cells, an
immortalized human neuronal cell line which actively
secretes serotonin, to enhance 5-HT levels near lumbar mo-
tor pools [23] and to partially recover locomotor func-
tion in the nude rat following severe contusive SCI. The
neurotransmitter 5HT is naturally present in the dorsal
and ventral horns of the spinal cord and in spinal path-
ways mediating nociceptive and motor function. However,
5HT is not likely to be present in adequate amounts
after nervous system injury to eﬀectively modulate the
sensory/motor imbalance that induces neuropathic pain and
motor impairments. Replacement or supplementation of
endogenous 5HT for sensory and motor recovery may be
a reasonable approach, since its loss after SCI is dependent
on injury severity [25] and correlates with loss of motor
function [26] and the alterations in the sensory system that
providean environment conduciveofneuropathicpain [27].
Unfortunately, pharmacologic modulation of 5HT is fraught
with methodological problems that could be overcome or
enhancedbyadependablesupplyofauthentic5HTproduced
by cellular minipumps located near (subarachnoid space) or
in (ventral motor centers) the spinal cord, rather than 5HT-
receptor agonists.
More than twenty years ago it was discovered that when
treated with retinoic acid (RA), a human embryonic carci-
nomacellline,NTera2cl.D/l(NT2),diﬀerentiatesirreversibly
into several morphologically and phenotypically distinct cell
types, including terminally diﬀerentiated postmitotc CNS
neurons [28]. Successive replating of RA-treated NT2 cells,
in the presence of growth inhibitors, results in the isolation
ofpuriﬁed humanneurons[29],which havebeenextensively
characterized and tested in vivo in a number of animal
models of traumatic injury and neurodegenerative disease
[28, 30]. Potential application of these progenitor NT2-
derived neurons in cell transplantation therapy for CNS
disorders has been demonstrated in Phase I-II clinical trials
for the treatment of stroke [31] and can likely be utilized for
further reparative transplant strategies.
One phenotype present within the NT2 parent popula-
tion synthesizes the inhibitory neurotransmitter 5HT [32].
From the variety of phenotypes expressed after diﬀerenti-
ation from NT2 cell line, we sought to subclone a human
neural cell line from the NT2 heritage that was speciﬁc to
the synthesis and secretion of 5HT, to characterize these cells
in vitro and test their ability to aﬀect nociceptive and motor
function in a SCI-pain/motor model. We have previously
described the use of 5HT cell therapy with a rat cell line that
is able to consistently reverse neuropathic pain after a par-
tial nerve injury [7]a n dh e m i s e c t i o nS C I[ 33]. Here we
expand on our previous investigations [23]w i t hh u m a n
hNT2.19 5HT-secreting cell grafts in the severe contusion
SCImodelofchronicpainandmotordysfunction andreport
ﬁndings with human neuronal 5HT cell therapy, where
hNT2.19 subarachnoid grafts are able to signiﬁcantly reduce
behavioral hypersensitivity, but not motor dysfunction.
2.Materialsand Methods
2.1. Development of the Human hNT2.19 and hNT2.6 Control
Cell Lines. Human neuronal cell lines were subcloned from
the parental NTera2cl.D/l (NT2) [34] cell line by serial
dilution, isolation of single cells that form colonies, and
analysis of multiple cell lines using a variety of immuno-
histochemical markers, including 5HT, to determine the
diﬀerentiated neurotransmitter phenotypeofthe various cell
lines. We took advantage of a rapid aggregation method
[35] for retinoic acid treatment and diﬀerentiation into the
human NT2-derived neuronal phenotype to select various
cell lines, as reported previously [18, 23]. Although we
derived a number of human NT2 neurotransmitter cell lines
by these methods, we have used the speciﬁc hNT2.19 cell
line for further characterization and transplant in severe
contusiveSCIpain.Additionally,anonserotonergicsistercell
line was isolated, named hNT2.6, and used as a negative
control in transplant studies.
The rapid aggregation method [35] for retinoic acid
treatment and diﬀerentiation was also used for the prepara-
tion of cultures of diﬀerentiated hNT2.19 and hNT2.6 cells
in vitro for characterization and transplant. Brieﬂy, prolifer-
ating cultures of hNT2.19 and hNT2.6 cells were grown to
near conﬂuenceat 37◦C inproliferationmedium: Dulbecco’s
Modiﬁed Eagle Medium/Ham’s F12 (DMEM/F12, Gibco)/
10%fetal bovine serum(FBS,HyClone,Logan, Utah)/2mM
L-glutamine (Gibco) freshly added/1% Pen-Strep (P.S.;
Gibco) with every 3rd day media change. When cells were
near 100% conﬂuent, they were replated to 100mm Petri
dish (VWR) in DMEM/high-glucose (HG)/10% FBS/10μM
all-trans retinoic acid (RA) (Sigma)/15mM HEPES, pH
8.0/2mM L-glutamine/1%Pen-Strep and continued for two
weeks, with fresh media changed every 2 days. After removal
with 0.5mM EDTA, centrifugation, and resuspension, cells
were replated to 100mm tissue culture dishes (Falcon) which
had been coated with mouse laminin [(Biomedical Tech-
nologies, Stoughton, MA; 20μg/mL in DPBS)/poly-L-lysine
(Sigma; 20μg/mL in PBS)]. They were then continued in
DMEM/high-glucose (HG)/5% FBS/1% Pen-Strep (P.S.)/L-
glutamine, 2mM, at a pH of 7.4, for 9–24hrs, before the
addition of cytosine-D-arabinofuranoside (araC) (Sigma;
1μM),plusuridine(Sigma;10μM), for nonneuronalgrowth
inhibition. After seven days, cells were brieﬂy exposed to
warmed trypsin/0.5mM EDTA and adherent surface cells
removed with DMEM/HG/5% FBS/P.S./L-glutamine, 2mM,
at a pHof7.4.These cells were centrifuged,resuspended,and
replatedon60mmtissueculturedishes(Falcon),coatedwith
mouse laminin [(Biomedical Technologies, Inc; 20μg/mL in
DPBS)/poly-L-lysine (Sigma; 20μg/mL)], and continued in
DMEM-HG/5% FBS/P.S./L-glutamine, 2mM at a pH of 7.4Neurology Research International 3
at 37◦C fortwo weeks before transplant, with media changed
every 2-3 days.
2.2. Immunohistochemistry of hNT2.19 Cells In Vitro. Mon-
oclonal antibody antibromodeoxyuridine (BrdU; #347580;
dilution 1:10) was purchased from Becton-Dickson, San
Jose, CA. Polyclonal antibody antiﬁbroblast growth factor-
4 (FGF-4; AF235; dilution 1:20) was purchased from R&D
Systems, Minneapolis, MN. The polyclonal antibody anti-
5HT (ab10385-50; dilution 1/100 (in vitro)) was purchased
from Abcam Inc, Cambridge, MA. The polyclonal antibody
anti-C-terminus of neuroﬁlament high (NFH;AB1989;dilu-
tion 1:100) was purchased from Chemicon (Millipore), Bil-
lerica, MA. Polyclonal antibody antihuman neuron-speciﬁc
enolase (hNSE;17437; dilution1:1000) was purchased from
Polysciences, Warrington, PA. Monoclonal antibody anti-
beta-tubulin III (TuJ1, MO15013; dilution 1:100) was pur-
chased from Neuromics, Edina, MN. The monoclonal anti-
body antitransforming growth factor-alpha (TGF-α; ab9578;
dilution 1:100) was purchased from Abcam Inc., Cam-
bridge, MA. The monoclonal antibody antineuroﬁlament
light (NFL; MCA-DA2; dilution 1:50) was purchased from
EnCor Biotechnology Inc, Alachua, FL. Monoclonal anti-
bodyanti-C-terminus ofanti-neuroﬁlament medium(NFM;
MCA-3H11; dilution 1:50) was purchased from EnCor
Biotechnology Inc, Alachua, FL. The hNT2-19 cells, after
two weeks of RA treatment and mitotic inhibitors, were re-
plated to diﬀerentiate in 8-well laminin/poly-L-lysine coated
Permanox slides, and diﬀerentiation continued for various
times before immunostaining. The cells were then ﬁxed for
10min at 4◦C with 4% paraformaldehyde and 0.1% gluter-
aldehyde in 0.1M phosphate buﬀe r ,p H7 . 4 .A l li m m u n -
ohistochemistry experiments included the use of a negative
control, substitution of speciﬁc primary antibody with
species IgG, to insure that positive signal was speciﬁc for
the antigen. For the BrdU immunostaining:a f t e rﬁ x a t i o n
and rinsing in PBS, pH 7.4 at room temperature, hNT2-
19 cells were incubated with 2N HCl for 20min at room
temperature, rinsed ×3 with PBS, incubated with borate
buﬀer (pH 8.5)/0.01M boric acid /0.5M Na borate (1:1)
for 15min at room temperature, rinsed for three times with
PBS,andthenpermeabilizedfor30minatroomtemperature
with blocking buﬀer before incubation with the primary
anti-BrdU antibody. For all other in vitro immunostaining
experiments: after ﬁxation and rinsing in PBS, pH 7.4 at
room temperature, ﬁxed hNT2-19 cells were permeabilized
for 30min at room temperature with 0.5% Triton X-100 in
PBS in the presence of 5% normal goat serum (the blocking
buﬀer), before the addition of the individual primary anti-
b o d y ,u s u a l l yo v e r n i g h ta t4 ◦C. The staining was completed
by incubation with the speciﬁc antispecies IgG secondary
conjugated to Alexa Fluor 488 Green (dilution 1:100),
purchased from Molecular Probe, Eugene, OR, for two
hours at room temperature. After staining, slides were cover-
slipped using Vectashield mounting medium with DAPI
(Vector Laboratories, Burlingame, CA). Photo images were
taken with a Zeiss microscope (Axioplan II Metamorphosis
program). All staining experiments were independently
repeated at least ×3, to insure that micrographs are repre-
sentative.
2.3. HPLC Analysis of hNT2.19 and hNT2.6 Cells In Vitro
2.3.1. 5HT and Catecholamines. In order to examine the
5HT and catecholamine content and release in diﬀerentiated
hNT2.19 and hNT2.6 cells, cells were diﬀerentiated for
2wksat37 ◦C after plating in 35mm laminin/poly-L-lysine-
coated 6-well plates. Cell numbers were determined in
sister wells by trypan blue exclusion and counting. Either
5HT/catecholamine content(in cells) or 5HT/catecholamine
release(intothemedia)wasexamined byHPLCtodetermine
the content or basal or stimulated level of 5HT and cate-
cholaminereleaseintothemedia.For5HTcontent,cellswere
collected into 1.5mL centrifuge tube (in distilled water),
cells broken by lysis with 0.05N PCA (perchloric acid), tube
contents centrifuged at 4◦C, and supernatant collected for
HPLC. Similar cell culture samples were also incubated with
either normal K+ (2.95mM) Krebs-Ringer buﬀer or high
K+ (100mM) buﬀer for 15min at 37◦Ca n dt h em e d i a
collected to determine the levels of 5HT or catecholamine
released into the media by membrane depolarization. The
media samples were kept on ice and immediately analyzed
by HPLC. The HPLC system consisted of a solvent-delivery
pump (Waters 510 Pump), an autosampler (Waters 717
plus Autosampler), and an electrochemical detector (ESA
Coulochem II); Electrode: ESA Microdialysis Cell 5014A
(DCCH1:−150mV, DCCH2:300mV, 500mA);GuardCell
Model 5020 (GC 350mV). Elution was carried out at room
temperature with a reversed-phase column (C18, 5μM, 150
× 3, BetaBasic-18, Thermo) and MDTM mobile phase
(ESA Inc. 70-1332); it consisted of 75mM of NaH2PO4,
1.7mM of C8H17O3SNa, 100μL/L of TEA, 25μMo fE D T A ,
10% acetonitrile, pH 3.0 adjusted by H3PO4 at a ﬂow rate
of 0.6mL/min. Ordinarily the norepinephrine appeared at
about 2.3min; the epinephrine at about 2.6min; 5HT at
about 7.5min.
2.4. Animal Study Design. Once the hNT2.19 and hNT2.6
cell lines were characterized with an understanding of the
neuronal phenotype and secretory properties, the eﬀect of
grafts of these cells on pain and motor behaviors after severe
contusiveSCIwasstudied.AdultfemaleSprague-Dawleyrats
(Harlan; approximately 200–250 grams) were used for all
behavioral experiments. The rats were housed 2 per cage
with rat chow and water ad lib on a 12/12hr light/dark cycle.
Ratswereacclimatedandpretrainedtotwobehavioralsenso-
ry tests: tactile allodynia (hindpaw withdrawal from a nor-
mally innocuous mechanical stimulus) and thermal hyper-
algesia (hindpaw withdrawal from a noxious heat source).
Additionally, and on alternate days, all animals were exam-
ined for motor behaviors, which included the BBB open-
ﬁeld testing. These tests were performed weekly (but on dif-
ferent days to reduce animal stress) for the duration of
the 60-day experiment. Additionally, before and at end of
the experiment before euthanasia, all animals were exam-
ined for four other motor behavioral tests: gridwalk error,4 Neurology Research International
degree of hindlimb rotation, base of hindlimb support,
and measurement of stride length. Following behavioral
baseline measures before any surgery, the animals then
underwent asevere contusiveSCI(25mm weight drop,NYU
impactor)toinducebehavioralhypersensitivity totactileand
thermal stimuli, as conﬁrmed by a vigorous response to
sensory behavioraltesting, anddevelopingpermanentmotor
dysfunction. Two weeks after injury or laminectomy only,
animals to be transplanted received either a lumbar intrathe-
cal cell graft with either hNT2.19 cells (diﬀerentiated for 2
weeks in vitro before transplant) or negative-control hNT2.6
cells. A third group of animals served as a control group and
received only the SCI but no transplant. A fourth group of
animals received laminectomy alone, rather than the SCI,
and served as surgery controls. Two additional groups of
rats received laminectomies, rather than full SCI, and were
transplanted atthetwo-weektime pointwitheitherhNT2.19
or hNT2.6 cells. All groups of animals received Cyclosporine
A (CsA) immunosuppression (i.p.,10mg/kg, daily) at the
time points corresponding to 1 day prior to and 13 days
following transplant. The animals were sacriﬁced after eight
weeks of behavioral testing and examined for the presence of
surviving grafted hNT2.19 or hNT2.6 cells.
All surgical interventions, pre- and postsurgical animal
care, and euthanasia were in accordance with the Laboratory
Animal Welfare Act, G u i d ef o rt h eC a r ea n dU s eo fL a b o r a t o ry
Animals (NIH, DHEW Pub. no. 78-23, Revised, 1978) and
guidelines provided by the Animal Care and Use Committee
oftheVeteran’sAssociationMedicalCenter(VAMC),Miami,
Fl. All behavioral testing was performed under blinded con-
ditions to eliminate experimental bias and data analyzed and
unblinded by the statistician at the end of the experiment.
Each speciﬁc intervention or test is described in detail below.
2.5. Contusive Spinal Cord Injury. Contusion injury was
induced by the weight drop device developed at New York
University [22]. Adult female Fischer rats (Harlan, n ≥
5; 200–250g) were housed according to NIH and USDA
guidelines. The Institutional Animal Care and Use Commit-
tee of the Miami VAMC approved all animal procedures.
Animals were anesthetized using an IP injection of a
mixture of ketamine (35mg/Kg) and xylazine (5mg/Kg), all
0.65mL/Kg, and then placed on a surgical table on a heating
pad (37 ± 0.5◦C) with pedal and eye blink reﬂexes assessed
for deep anesthesia before beginning procedures. The back
region was shaved and aseptically prepared with betadine.
Lacrilube ophthalmic ointment (Allergan Pharmaceuticals,
Irvine, CA) was applied to the eyes to prevent drying and
bicillin (0.02mL/100mg body weight, 300U/mL; J. Buck,
Inc., Owings Mills, MO) administered intramuscularly.
Following anesthesia, a vertical incision was made along the
thoracic vertebra and the superﬁcial muscle and skin
retracted. A laminectomy performed at thoracic vertebra T7
exposedthedorsalsurfaceofthespinalcordunderneath(T8)
without disrupting the dura mater. Stabilization clampswere
placed around the vertebrae at T6 and T12 to support the
columnduring impact. The exposed spinal cord was severely
injured by dropping a 10.0g rod from a height of 25.0mm.
The contusion impact velocity and compression were mon-
itored to guarantee consistency between animals. After
injury, the muscles were sutured in layers and the skin closed
withabsorbablesutures(Ethicon,Inc).The ratswereallowed
to recover in a warmed cage with water and food easily
accessible. Bicillin (0.02mL/100mg body weight, 300U/mL,
i.m.)wasadministered 2,4,and6dafterthecontusioninjury.
The rats were maintained for 8wks after injury, including
gentle twice daily manual bladder expression to prevent the
development of cystitis.
2.6. Cell Culture and Transplant of hNT2.19 and hNT2.6
Cells. The hNT2.19 5HT and control hNT2.6 cells that had
been prediﬀerentiated (as above) for 2 weeks in vitro were
prepared fortransplant studies.Brieﬂy,cellswere rinsed with
warmed Cellstripper (Voigt Global Dist.), media replaced
with another 3mL of Cellstripper for one minute, and then
rinsed withwarmed Hank’sbuﬀeredsalt solution(HBSS)for
complete cell removal from the TC plate. Viability and cell
counts were assessed by trypan blue exclusion, and the cells
were suspended in 100μlo fC a 2+-Mg2+-free Hank’s buﬀered
saline solution (CMF-HBSS). An aliquot of one million
cells (1 × 106 cells/10μLb u ﬀer) was prepared immediately
prior to each transplant to assure near 100% viability at the
beginning of the experiment; grafting was within 30min of
cell preparation.
The animals to be transplanted, one day after show-
ing a vigorous response to behavioral testing, were anes-
thetized with a mixture of ketamine, xylazine, and acepro-
mazine (0.65mL/kg). For subarachnoid grafts, the previous
laminectomy site (T7) was exposed and a small dural and
arachnoidal incision was made and a 2-3mm segment of
polyethylene (PE-10) tubing, connected to a micropipette,
inserted through the durotomy in a caudal direction. The
one million cells (hNT2.19 or hNT2.6) were injected into
the intrathecal space at spinal segment L1–L3 and the fascia
a n ds k i nc l o s e d .A g a i n ,n oa d d i tional analgesia was used.
The animals were allowed to recover at 37◦Cf o r1 2h r s ,a f t e r
which time they were returned to the animal care facility. All
rats, including those not provided cell transplants, received
immunosuppressive therapy with CsA, injected i.p., which
began one day before cell transplant and continued daily for
13 days.
3.BehavioralTesting
3.1. Thermal Hyperalgesia Testing. Methods for testing ther-
mal hyperalgesia with a Hargreaves device have been de-
scribed elsewhere [36]. Animals were placed in a clear plex-
iglass box on an elevated plexiglass ﬂoor. Animals were
allowed to acclimate for approximately 5min. A constant
intensity, radiant heat source was aimed at the midplantar
area of the hind paws. The time, in seconds, from initial heat
source activation until paw withdrawal, was recorded. Five
minutes were allowed between assessments. Three to four
latency measurements for each paw were recorded and the
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each hindpaw. Animals were tested 3 times, one week apart,
for 2wks prior to the injury (baseline) and then weekly for
the duration of the experiment. In order to provide a robust
baseline value for comparison purposes, baseline data was
averagedto a mean baseline based on the three baseline tests.
3.2. Tactile Allodynia Testing. Mechanical allodynia, the
occurrence of foot withdrawal in response to normally
innocuous mechanical stimuli, was tested using an auto-
mated, electronic von Frey anesthesiometer (IITC, Inc) [37].
Animals were placed in a plexiglass box with an elevated
mesh ﬂoor. After the animal was acclimated for 5min, the
device tip was applied perpendicular to the midplantar area
of each hindpaw and depressed slowly until the animal with-
drew the paw from pressure. The value, in grams, was re-
corded for each of the 3 trials. A single trial of stimuli
consisted of three to four applications of the von Frey tip
within a 10-second period, to ensure a consistent response.
The values obtained for each hindpaw were averaged and
the SEM calculated. The animals were tested 3 times, one
week apart, for 2-3wks prior to the injury (baseline) and
then weekly for the duration of the experiment. In order to
provide a robust baseline value for comparison purposes, all
baseline data was averaged to a mean baseline based on the
three baseline tests.
3.3. BBB Motor Behavior Testing. Two wks prior to the
injury, open-ﬁeld locomotor functions of all animals were
assessed using the Basso, Beattie, and Bresnahan (BBB)
locomotor rating scale [38]. Behavioral assessments were
then performed on days 1 and 7 following the injury and
weekly thereafter. The BBB score was used to study the func-
tional recovery stages following the injury, by categorizing
the rat hindlimb movements, trunk position and stability,
coordination, stepping and paw placement and tail position.
Rats were placed in a small, shallow, empty children’s swim-
ming pool and allowed tomove freely for60mins ofexercise,
during which their motor behaviors were observed and
scored according to the BBB scale. All observations were
made by at least two independent observers, who were
unaware of the extent or nature of the injury. The animals
were rated on a scale of 0 to 21.
3.4.FootprintAnalysis andGridwalkFootfallError. Footprint
analysis was performed before and at 8 weeks postinjury
using a modiﬁed protocol by de Medinaceli et al. [39]. The
animal’s fore and hind paws were inked with diﬀerent colors
to record footprints on paper that covered a narrow runway
of 1m in length and 7cm in width. A series of at least eight
sequential steps were used to determine the mean values for
eachmeasurementoflimbrotation,stridelength,andbaseof
support. The base of support was determined by measuring
the core-to-core distance of the central pads of the paws.
The limb rotation was deﬁned by the angle formed by the
intersection of the line through the print of the third digit
and the line through the central pad parallel to the walking
direction. Stride length was measured between the central
pads of two consecutive prints on each side. Forthe gridwalk
test, deﬁcits in descending ﬁne motor control was examined
at 8 weeks postinjury by assessing the ability to navigate
across a 1mlong runway with irregularly assigned gaps (0.5–
5.0cm)betweenroundmetalbars,asdescribedpreviouslyby
Metz et al. [40]. Crossing this runway required that animals
accurately place their limbs on the bars. In baseline training
and postinjury testing, every animal crossed the grid at least
three times. The numbers of footfalls (errors) for hindlimbs
were counted in each crossing, and a mean error rate was
calculated.
3.5. Immunohistochemistry In Vivo. For immunohistochem-
istry of sectioned spinal cord tissues, the polyclonal antibody
anti-5HT (ab10385; dilution 1/100 (in vivo)) was purchased
from Abcam Inc, Cambridge, MA, and the antihuman TuJ1
antibody (Neuron-speciﬁc class III beta-tubulin) was pur-
chased from Neuromics, Edina, MN (MO15013; dilution
1/100 (in vivo).
3.6. Fixation. Spinal cords were ﬁxed to examine cell graft
survival and 5HT and TuJ1 staining, 8 weeks after contusive
SCI (6 weeks after transplant). Transcardial perfusion with
4% paraformaldehyde [41] and 0.1% glutraldehyde was
performed. Rats were euthanized for tissue ﬁxation by a
combination of pentobarbital overdose and exsanguination.
Animals were anesthetized with an interperitoneal injection
of sodium pentobarbital (12mg/100g). Once the appro-
priate level of anesthesia was reached (i.e., no corneal or
withdrawal reﬂexes), the rat was transcardially perfused with
the aldehydes. After perfusion, the spinal cord, including
transplant, was removed and histologically processed. After
removal from the vertebral column, cords were stored in
ﬁx for 12hrs, 4◦C. The cords were cryoprotected by equi-
libration in 30% sucrose and PBS overnight, 4◦Ca n dt h e n
f r o z e na n ds t o r e da t−80◦C. Cords were embedded in
Shandon M-1 Embedding Matrix (Thermo Electron Corp.)
andsagittallycutinsequential20μmsectionswithaCry ostat
(Leica1900).They werecollectedonnoncoatedslides(micro
Slides, Snowcoat X-tra (Surgipath)). The slides were stored
in a −20◦C freezer and removed for defrosting before the
immunostaining procedures. Every second section was
stained for the human marker TuJ1 or 5HT and dehydrated,
cleared, and mounted in Cytoseal 60 (Richard-Allan Scien-
tiﬁc) after antibody staining. Processed slides were observed
and photographed with a Nikon Digital Imagining Eclipse
90i Research Microscope.
3.7. TuJ1 Staining. Modiﬁed methods for staining spinal
cord sections for the human neuron-speciﬁc class III beta-
tubulin (TuJ1) to identify grafted hNT2.19 and hNT2.6
neurons after grafting have previously been described [42].
The sections were washed with 0.1MPBS pH 7.4 and
permeabilized with 0.4% Triton-X-100 in 0.1MPBS, 10%
normal goat serum (NGS) for one-hour. The sections were
then incubated overnight at 4◦C in the primary anti-TuJ1
antibody (1/100DPBS), and the permeabilizing solution,
followed by a one hour incubation at room temperature
with the secondary antibody solution, biotinylated mouse6 Neurology Research International
(a) (b)
(c) (d)
Figure 1: Morphology of the diﬀerentiation of the hNT2.19 and hNT2.6 cell lines in vitro. The hNT2.19 and hNT2.6 cell lines were treated
for two weeks with retinoic acid (RA) and mitotic inhibitors and lifted to substrate-coated 8-well plastic tissue culture (TC) slides for
diﬀerentiation and phase microscopy. As soon as 1 day of diﬀerentiation in culture under these conditions (a), hNT2.19 cells extend
multipolar ﬁbers, which are clearly visible at three days (b). The hNT2.19 cells continue to extend multiple ﬁbers, forming a dense ﬁber
network by 2wks (c). The negative control hNT2.6 cells appear quite similar at 2wks of diﬀerentiation (d). Magniﬁcationbar = 10nm, (c);
magniﬁcation bar = 20nm, (a, b, d).
IgGraised ingoat(Vector;1/200),a PeroxidaseABCreporter
in 0.1MPBS (Vector), and “VIP” substrate (Vector). Some
sectionswere stainedintheabsenceofprimary antibody,and
served as the negative controls.
3.8. 5HT Staining. Methods for staining lumbar spinal
cord sections for 5HT and grafted hNT2-derived cell lines
have been adapted from methods described elsewhere [23].
Sections were incubated with the primary antibody 5HT
(1/100) with 0.4% Triton-X-100 in 0.1MPBS and 10% NGS
o v e r n i g h ta t4 ◦C, followed by a one-hour incubation at
room temperature with the secondary antibody solution,
biotinylated anti-rabbit IgG (H + L), made in goat (Vector;
1/200) in 0.4% Triton-X-100 in 0.1MPBS and 10% normal
goat serum (NGS), a Peroxidase ABC reporter in 0.1MPBS
(Vector), and “VIP” substrate (Vector). Some sections were
stained in the absence of primary antibody, and served as the
negative controls.
3.9. Statistical Analysis. Statistical analyses were performed
with PASW 17.0 for Windows. To determine diﬀerences
between the groups and between time points, we used one-
way analysis of variances (ANOVAs) and paired Student’ t-
tests. All t-tests were two tailed, and we used Bonferroni
correction to adjust for multiple comparisons. A P value
of .05 or less was considered statistically signiﬁcant.
4.Results
4.1. hNT2.19 Cell Line Characterization In Vitro
4.1.1. The hNT2.19 Cell Line Has a Neuron-Like Morphology
during Diﬀerentiation over Time In Vitro. Once the hNT2.17
cells begin diﬀerentiation, after treatment with retinoic
acid and mitotic inhibitors in vitro, they can easily be
transferred to substrate-coated surfaces. When examined by
phase microscopy during diﬀerentiation (Figure 1), the cells
appear to have extended multipolar neuron-like processes
as soon as one day in vitro (Figure 1(a)). By seven days,
cells have begunto form dense ﬁbers networks (Figure 1(b)).
Within two weeks (Figure 1(c)), the cells continue to extend
long ﬁbers, but aggregate as balls of cells, eventually formingNeurology Research International 7
(a) (b) (c)
Figure 2: The BrdU signal in proliferating versus diﬀerentiating hNT2.19 cells in vitro. The hNT2.19 cells were either exposed to 1μMB r d U
during 3 days of proliferation (a) or for 1 week during diﬀerentiation (b, c) in vitro. With an antibody directed against BrdU, proliferating
cells incorporate abundant BrdU during proliferation (a). Viable diﬀerentiated cells were co-labeled with a DAPI stain (b), while the same
ﬁeld of diﬀerentiated cells did not incorporate any BrdU during diﬀerentiation (c). After two weeks of retinoic acid and mitotic inhibitors,
the hNT2.19 cells cease dividing during diﬀerentiation, and did not incorporate BrdU. Magniﬁcation bar = 20nm, (a); magniﬁcation bar =
30nm, (b, c).
dense networks of ﬁbers extending from the balled cells. The
control hNT2.6 cells, here seen at 2 weeks of diﬀerentiation
(Figure 1(d)), are nearly indistinguishable from the hNT2.19
cells. Both cell lines have been kept as long as 50 days of
diﬀerentiation in culture, forming very dense ﬁber networks
that cover the plate surface.
4.1.2. The hNT2.19 Cells Incorporate BrdU with Proliferation
butNotDiﬀe r e n ti a ti o nI nV i tr o . Bromodeoxyuridine(BrdU)
immunostaining has been used a marker for proliferating
cells in vitro [43]a n di nv i v o[ 44], since dividing cells
incorporate BrdU-labeled uridine into newly made DNA.
The hNT2.19 cells were exposed to 1mM BrdU in vitro
during either proliferation or during diﬀerentiation before
anti-BrdU immunostaining. Following 3 days of prolifera-
tion in the presence of BrDU (Figure 2(a)), the BrdU signal
is intense and found in all the dividing cells. After one week
of BrdU exposure during the ﬁrst week of diﬀerentiation,
hNT2.19 cells remained viable, as evidenced by DAPI stain-
ing (Figure 2(b)). The same ﬁeld of diﬀerentiated hNT2.19
cells showed no anti-BrdU signal (Figure 2(c)).
4.1.3. Diﬀerentiated hNT2.19 Cells Cease to Express Markers
of Tumorgenicity with Diﬀerentiation In Vitro. The question
of possible tumorgenicity in the eventual clinical use of any
diﬀerentiated cells is relevant to their characterization in
vitroandinvivo[45].Twoimportant tumormarkers, TGF-α
andTGF-4,areassociatedwithhumanembryoniccarcinoma
(EC) and NT2 cells. The parental NT2 cells are classiﬁed
as EC cells because of their testicular germ cell origin and
that they express the same cell-surface antigens during pro-
liferation. Exposure of NT2 (proliferating) cells to retinoic
acid results in postmitotic hNT2 cells, which do not form
tumors or revert to a neoplastic state with transplantation
[46]. A similar NT2-derived cell line, hNT2.17, has been
characterized in vitro and in vivo and does not express
tumor markers with diﬀerentiation in vitro or form tumors
after transplant [18]. Undiﬀerentiated NT2 cells express
the protein TGF-α, which is involved in stimulation of
cell proliferation [47], which decreases after RA treatment.
Undiﬀerentiated NT2 cells also express the protein FGF-
4, which is abundant in a subset of germ cell cancers and
promotes malignant growth of cultured ECs. Like TGF-α,
it is repressed in NT2 cells after RA treatment [48]. When
hNT2.19cellsaretreated withRAandmitoticinhibitors,and
diﬀerentiated in vitro, they cease to express both TGF-α and
FGF-4. Proliferating hNT2.19 cells express abundant TGF-α
and FGF-4 (Figures 3(a) and 3(d), resp.). After one week of
diﬀerentiation, viable hNT2.19 cells (Figures 3(b) and 3(e),
DAPI-stained) express no detectible TGF-α (Figure 3(c))
or FGF-4 (Figure 3(f)), both compared to viable DAPI-
stained wells), suggesting they are no longer tumorigenic
in vitro following RA treatment, mitotic inhibitors, and
diﬀerentiation.
4.1.4. The hNT2.19 Cells Express Human and Neural Markers
with Diﬀerentiation. Critical to the identity of the diﬀer-
entiated hNT2.19 cells is that they are exclusively neu-
rons. Immunostaining with glial ﬁbrillary acidic protein or8 Neurology Research International
(a) (b) (c)
(d) (e) (f)
Figure 3: The tumor markers, TGF-α and FGF-4, in diﬀerentiating and proliferating hNT2.19 cells in vitro. In other sister cultures, the
hNT2.19 cell linewaseitherproliferated andstainedforTGF-α (a)ortreated fortwo weeks withRAandmitoticinhibitorsanddiﬀerentiated
for one week (b, c) before TGF-α staining. Viable cells were located with DAPI stain (b). The same ﬁeld of diﬀerentiated cells expressed no
detectible TGF-α (c),while the signalwas abundantin proliferatingcells (a).In anotherset of sistercultures, the hNT2.19 cell line waseither
proliferated and stained for FGF-4 (d) or treated for two weeks with RA and mitotic inhibitors, and diﬀerentiated for one week (e, f). Viable
cells were located with DAPI stain (e). The same ﬁeld of diﬀerentiated cells expressed no detectible FGF-4 (f), while the signal was abundant
in proliferating cells (d). Diﬀerentiated hNT2.19 cells do not express the tumor markers FGF-α or TGF-4. Magniﬁcation bar = 20nm, (d);
magniﬁcation bar = 30nm, (a, b, c, e, f).
vimentin antibodies did not result in a glial or proliferating
precursorsignalinhNT2.19cellsduringdiﬀerentiation(data
not shown), features also demonstrated in the NT2 parent
cell line [28] and the similar NT2-derived hNT2.17 cell line
[18].However, variousneuron-speciﬁc markers were present
assoonas4daysofdiﬀerentiation:TuJ1(humanneuronspe-
ciﬁc beta III tubulin protein), in hNT2.19 (Figure 4(a))a n d
hNT2.6 (Figure 4(f)) cells, human NSE (Figure 4(b)), NFL
(Figure 4(c)), NFM (Figure 4(d)), and NFH (Figure 4(e)).
These stained intensely until at least 6wks of diﬀerentiation
in vitro. TuJ1 has been commonly used to identify human
neuronal cells in vitro and in vivo [42].
4.1.5. The hNT2.19 Cell Line Expresses a Serotonin Neuro-
transmitter Phenotype with Diﬀerentiation. Easily observed
during the early diﬀerentiation period with an antibody
stain for 5HT, all the hNT2.19 cells stain for the neu-
rotransmitter 5HT (Figures 5(a) and 5(b)). Both the cellNeurology Research International 9
(a) (b) (c)
(d) (e) (f)
Figure 4: Neural and human markers with diﬀerentiation of the hNT2.19 cell line in vitro. The hNT2.19 cell line was treated for two weeks
withretinoic acidandmitoticinhibitorsandlifted to substrate-coated 8-well plasticTC slidesfordiﬀerentiationandimmunohistochemistry
for neuron-speciﬁc markers. As soon as 4 days in vitro, a variety of neural markers appeared, which remained strong until at least 6wks of
diﬀerentiation: TuJ1 (a), hNSE (b), NFL (c), NFM (d), and NFH (e). For comparison, the negative control hNT2.6 cell line was cultured
similarly as the hNT2.19 cells and is here stained for TuJ1 (f). Magniﬁcation bar = 20nm, (a–f).
soma and extending ﬁbers contain a strong 5HT signal.
As the ﬁbers extend during diﬀerentiation, the ﬁber 5HT
signal becomes concentrated, punctate-like, in bouton-like
structures. Any similar immunostaining for 5HT in hNT2.6
cells (Figure 5(c)) was not detectable.
The hNT2.19 staining for other neurotransmitter phe-
notypes was negative, with no signals seen for choline
acetyltransferase (ChAT), responsible for acetylcholine syn-
thesis; tyrosine hydroxylase (TH), the rate-limiting enzyme
for catecholamine synthesis; dopamine beta hydroxylase
(DBH), which converts dopamine to norepinephrine; phe-
nylethanolamine-methyltransferase (PNMT), which con-
verts norepinephrine to epinephrine; calcitonin gene related
peptide (CGRP); galanin; substance P; gamma aminobutyric
acid (GABA); glycine; NMDA receptor 1 (NMDAR1); or
chromagranin markers.
4.1.6. HPLC for Serotonin (5HT) and Norepinephrine
(Norepi) Synthesis and Release of Neurotransmitters in
hNT2.19 and hNT2.6 Cells. The hNT2.19 and hNT2.6 cell
lines were diﬀerentiated for two weeks in vitro, before HPLC
analysis of 5HT and norepi content, basal secretion in the
presence ofbasal K+(2.95mM)and stimulatedrelease in the
presence of high K+ (100mM) in the media in the hNT2.19
(Figure 6(a))a n dh N T 2 . 6( Figure 6(b)) cells. The hNT2.19
cell line was able to synthesize signiﬁcant amounts of the10 Neurology Research International
(a) (b) (c)
Figure 5: The hNT2.19 cell line expresses a 5HT phenotype with diﬀerentiation in vitro. The hNT2.19 cell line was treated for two weeks
withretinoic acidandmitoticinhibitorsandlifted to substrate-coated 8-well plasticTC slidesfordiﬀerentiationandimmunohistochemistry
for 5HT. All the hNT2.19 cells stain very brightly for the neurotransmitter 5HT (a, b). Both the cell soma and extending ﬁbers contain a
strong 5HT signal. As the ﬁbers extend during diﬀerentiation, the ﬁber 5HT signal becomes concentrated, punctate-like, in bouton-like
structures, as early as 2wks in vitro (b). The negative control hNT2.6 cell line is seen in (c) after an anti-5HT immunostain;no 5HT signal
is seen. Magniﬁcation bar = 20nm, (a–c).
5HT neurotransmitter, matching the immunohistochemical
staining patterns seen above. The norepi content (synthe-
sized) in hNT2.19 was near zero. Mean 5HT content was
485.130 SEM (58.697)pmoles per 10 million cells (n = 25).
The hNT2.19 cell line also demonstrated signiﬁcant 5HT
release under basal or potassium-stimulated conditions, at
t h et i m ep o i n td u r i n gd i ﬀerentiation when these cells were
transplanted in the severe contusion SCI pain model. Mean
5HTrelease underbasal(73.381SEM(16.415)pmolesper10
million cells, n = 21) or stimulated K+ conditions (85.640
SEM (10.515)pmoles per 10 million cells, n = 23) over
15mins was able to account for more than 38% of the
total 5HT content in the cell cultures. Mean norepi content
(40.154 SEM (10.867)pmoles per 10 million cells, n = 13)
and secretion (0.0pmoles per 10 million cells, n = 13) or
release (0.0pmoles per 10 million cells, n = 13) in the
presence of basal and high concentrations of KCl suggested
that even though hNT2.19 cells were able to make a very
small amount of norepi, they did not release or secrete
norepi into the cellular environment. The control hNT2.6
celllinewas abletosynthesize onlyvery small amountsofthe
5HT neurotransmitter, suggested by the lack of 5HT signal
in the immunohistochemical staining patterns seen above.
The norepi content (synthesized) in hNT2.6 cells was near
zero. Mean 5HT content was 78.683 SEM (33.500)pmoles
per 10 million cells, n = 6. The hNT2.6 cell line also
demonstrated no measurable 5HT release under basal or
potassium-stimulated conditions, at the time point during
diﬀerentiation when these cells were transplanted in the
severe contusion SCI pain model. Mean 5HT release were
zero under basal or stimulated K+ conditions. Mean norepi
content, secretion, and release was zero in hNT2.6 in the
presence of basal and high concentrations of KCl, which
suggested that even though hNT2.6 cells were able to make
a very small amount of 5HT, they did not release or secrete
5HT or norepi into the cellular environment.
4.2. Characterization of the Grafts of hNT2.19 Cells
4.2.1. Immunohistochemistry of the hNT2.19 Cells after
Transplant and SCI. Adult female Wistar Furth rats were
injured by contusive SCI induced by the weight drop device
and transplanted with intrathecal hNT2.6 (Figures 7(a) and
7(b)) or hNT2.19 (Figures 7(c) and 7(d))g r a f t s ,w h i c hh a d
beenprediﬀerentiatedfortwo weeksinvitro. Transplant sites
(thoracic/lumbar spinal cord) collected 8 weeks after SCI
were visualized with speciﬁc human and neurotransmitter
antibody markers TuJ1 (Figures 7(a) and 7(c))a n d5 H T
(Figures 7(b) and 7(d)). Many of these grafted cells survive
(Figures 7(a) and 7(c), arrows) on the pia near the lumbar
cord for at least 8 weeks after SCI, and apparently only
the hNT2.19 cells retain their 5HT (compare hNT2.6 cells
in Figure 7(b) and hNT2.19 cells in Figure 7(d)) expression
after transplant in a severe contusive SCI model.
4.2.2. Sensory Behaviors after Lumbar Subarachnoid Trans-
plant of hNT2.19 Cells. In this study the animals were
divided into 6 diﬀerent experimental groups: (1) Group 1
(Laminectomy); (2) Group 2 (Contusion); (3) Group 3
(Contusion + hNT2 6 cells); (4) Group 4 (Contusion +
hNT2 19 cells); (5)Group 5 (Laminectomy + hNT2 19 cells);
(6) Group 6 (Laminectomy + hNT2 6 cells). The sensoryNeurology Research International 11
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Figure 6: HPLC analysis: 5HT and norepinephrine content (synthesis), secretion, and release in hNT2.19 and hNT2.6 cells in vitro. The
hNT2.19 (a) and the hNT2.6 (b) cell lines were diﬀerentiated, after RA and mitotic inhibitor treatment, for two weeks in 6-well substrate-
coated plates before cell lysis and examination of cell content for 5HT or norepinephrine by HPLC methods. For 5HT and norepinephrine
secretion (basal)and release (stimulated), sister cultures of the hNT2.19 and hNT2.6 cells were diﬀerentiated fortwo weeks before cells were
exposed to basal (2.95mM) or high (100mM) concentrations of KCl for potassium (K+)-stimulated release for 5HT and norepinephrine
measurementinthemedia.Datarepresent themean+SEMfrom6–18samplesfrom>3independentexperiments foreachneurotransmitter.
Only the hNT2.19 cells contain any 5HT, which is either secreted or released into the extracellular environment; the hNT2.6 cells do not
secrete or release 5HT outside the cells. Neither cell line makes, secretes, or releases the neurotransmitter norepinephrine.
evaluation included tactile allodynia (TA) and thermal
allodynia (TH).
In order to provide a basis for the treatment of chronic
sensory and motor dysfunction after SCI with neurotrans-
mitter cell therapy, it is critical to examine the eﬀects of
hNT2.19 cell therapy on sensory behaviors in a severe
weight dropcontusiveSCImodel (Figure 8).Consistent with
our previous studies in contusive and other SCI models,
evaluatingmotor and sensory behaviors [49]in combination
with cell therapy [23], about one week was required for
signiﬁcant tactile allodynia and thermal hyperalgesia to
develop[18].Inourhands, contusiveSCIinducedsigniﬁcant
and bilateral thermal and tactile hypersensitivity in the
hindpaws, beginning at about 7 days. The induced sensory
abnormalities were not signiﬁcantly diﬀerent between the
two hindpaws for either TA or TH, and therefore, the ipsi
and contralateral sensory thresholds values were averaged.
The sensory abnormalities induced by the injury continued
without diminution for 60 days, until the animals were
sacriﬁced. Saline (vehicle) injected animals developed no
measurable or signiﬁcant mechanical allodynia or thermal
hypersensitivity (data not shown).
All animals were tested behaviorally at three occasions,
one week apart, during two weeks before SCI to establish
baseline measures. The behavioral testing continued for 56
d a y sa f t e rS C If o rT Aa n dT H( Figure 8) as described in
Section 2.
Baseline. The baseline values were calculated as one average
TA and one average TH value. Each average value was based
on the ipsi and contralateral threshold values and on the
three baseline assessments to increase the robustness of the
baseline. ANOVAs (Tables 1(a) and 2(a)) comparing the
average TA (n = 37; 34.7 SEM 0.9) and the average TH (n =
37; 14.48 SEM 0.07) values showed no signiﬁcant diﬀerences
among the groups (TA: F = 1.03, ns; TH: F = 1.46, ns).
Within-Group Comparisons. As expected, laminectomy
alone (Group 1) or laminectomy followed by cell transplant
(Groups 5 and 6) did not have any signiﬁcant sensory eﬀects
over the 60-day period except for Group 1 where TA was
slightly higher (P<. 05) at day 35, and the TH at day 21
and 28 was slightly lower (P<. 01) compared to baseline,12 Neurology Research International
(a) (b)
(c) (d)
Figure 7: Transplant of hNT2.19 and hNT2.6 cell lines in the severe contusive SCI model: TuJ1 and 5HT immunohistochemistry. Rats were
injured with severe contusive SCI followed at two weeks by hNT2.6 (a, b) or hNT2.19 (c, d) cell grafts. Sagittal spinal cord sections were
examined at 8wks after SCI for evidence of surviving lumbar subarachnoid hNT2.6 (a, b) or hNT2.19 (c, d) cell line grafts, utilizing TuJ1
(a, c) or 5HT (b, d) immunohistochemistry. The hNT2.19 and control hNT2.6 (106 cells/injection), which had been diﬀerentiated for two
weeks in vitro, were injected into the subarachnoid space two weeks after the SCI. Cell graft sites were colocalized with 5HT (b, d) and the
human-speciﬁc marker TUJ1 (neuron-speciﬁc class III β-tubulin; (a, c)). There are many surviving hNT2.19 (c) and hNT2.6 (a) grafted
cells visible on the pial surface, which stain for TuJ1 (arrows) at the end of the experiment, 56 days after SCI and about 6 weeks after cell
transplant.Adjacent sections with the samegrafted hNT2.19 (d) and hNT2.6 cells (b) are stained for5HT, but onlythe hNT2.19 cells (d) are
labeled for 5HT (arrows).
suggesting slight variations between (uninjured) animals
(Tables 1(a) and 2(a), Figure 8). However, SCI animals
(Group 2) developed signiﬁcant behavioral hypersensitivity
to both thermal and tactile stimuli with signiﬁcantly
(P<. 001, Bonferroni corrected) lower thresholds on all
time points compared to baseline (t ranging from −10.66 for
t7t o−22.09fort14forTAand t ranging from −15.74fort14
to −74.82 for t42). After SCI, a signiﬁcant hypersensitivity
to heat was observed about 7 days after SCI that was near
maximal at one to two weeks, with mechanical allodynia
usually appearing a day or two earlier. The behavioral
hypersensitivity responses were not recovered or diminished
by 60 days after injection. Transplant of hNT2.19 cells
(Group 4) provided permanent attenuation of behavioral
hypersensitivity, when transplants were done 14 days after
SCI (see Figures 8(a) and 8(b),a n dT a b l e s1 and 2).
Between-Group Comparisons. The ANOVAs and post hoc
comparisons shown in Tables 1(a) and 1(b) Tables 2(a)
and 2(b) show that both the TA and TH values diﬀered
signiﬁcantly among groups at all time points after the injury
(P<0.000; see Tables 1 and 2)w i t ht h eg r e a t e s td i ﬀerences
among groups being 35 days after injury (F = 302.5f o rT A
and F = 232.5 for TH). Post hoc analysis (Bonferroni) was
used to compensate for multiple comparisons and to show
signiﬁcant diﬀerences among groups. Both TA (Figure 8(a)
and Tables 1(a) and 1(b)) and TH (Figure 8(b) and Tables
2(a) and 2(b))) were signiﬁcantly attenuated by the graft
of hNT2.19 cells after contusion injury compared to injury
alone (t21 to t56 (P<0.000)) or to graft of nonserotonergic
hNT2.6 cells (t21 to t56 (P<0.000)).
In SCI animals (Group 2), the average mean latency
score for TA was 16.8g (SEM 1.52) at two weeks after SCI.Neurology Research International 13
Table 1: (a) ANOVA showing tactile allodynia thresholds, (b) Post hoc tests for tactile allodynia (Bonferronicorrected P values shown).
(a)
Time after
contusion
Group 1:
laminectomy
N = 5
Group 2:
contusion
N = 7
Group 3:
contusion +
hNT2-6
N = 6
Group 4:
contusion +
hNT2-19
N = 7
Group 5:
laminectomy +
hNT-19
N = 5
Group 6:
laminectomy +
hNT2-6
N = 7
One way ANOVA
Mean (SEM) Mean (SEM) Mean (SEM) Mean (SEM) Mean (SEM) Mean (SEM) F-statistic,
P value
Baseline 34.2 (0.13)a 34.8 (0.24)b 34.8 (0.1)c 34.8 (0.23)d 34.6 (0.16)e 34.7 (0.28)f 1.03, P = .417
7 34.0 (0.51)a 17.8 (1.45)b NA NA NA NA 81.9, P<. 000
14 (10)∗ 34.5 (0.26)a 16.8 (1.52)b 17.3 (0.81)c 17.6 (0.62)d 34.8 (0.17)e 35.4 (0.39)f 175.9, P<. 000
21 34.5 (0.28)a 15.9 (0.86)b 18.1 (0.91)c 27.2 (0.98)d 34.2 (0.18)e 34.5 (0.29)f 139.2, P<. 000
28 34.5 (0.15)a 16.4 (0.74)b 16.8 (0.61)c 28.4 (0.60)d 34.0 (0.28)e 34.4 (0.27)f 264.4, P<. 000
35 34.9 (0.14)a 16.6 (0.79)b 17.2 (0.63)c 29.8 (0.48)d 34.1 (0.10)e 35.0 (0.14)f 302.5, P<. 000
42 34.4 (0.17)a 16.7 (0.56)b 16.8 (0.80)c 31.0 (0.59)d 34.7 (0.44)e 34.8 (0.28)f 282.0, P<. 000
49 34.8 (0.28)a 17.0 (0.64)b 17.2 (1.09)c 31.1 (0.25)d 33.4 (0.40)e 33.7 (0.27)f 217.2, P<. 000
56 34.9 (0.11)a 17.0 (0.50)b 16.7 (0.99)c 32.2 (0.47)d 34.0 (0.14)e 34.1 (0.26)f 291.8, P<. 000
∗Time after contusion t14 is 10 days for groups 2, 3, 4 and 14 days for 1, 6, and 7.
Post hoc analyses (Bonferroni):
aGroup 1 is signiﬁcantlydiﬀerent than Groups 2, 3, 4 on all time points.
bGroup 2 is signiﬁcantlydiﬀe r e n tt h a nG r o u p s1 ,4 ,5 ,6a ta l lt i m ep o i n t se x c e p tf o rt14 when it is not signiﬁcantlydiﬀerent from group 4.
cGroup 3 is signiﬁcantlydiﬀe r e n tt h a nG r o u p s1 ,4 ,5 ,6a ta l lt i m ep o i n t se x c e p tf o rt14 when it is not signiﬁcantly diﬀerent from group 4.
dGroup 4issigniﬁcantlydiﬀerent fromallgroups ontimes21,28,35,42;t14:signiﬁcantlydiﬀerentfromgroups 1,5,6;t49:allbutgroup 5;t6:allbut5 and 6.
eGroup 5 issigniﬁcantlydiﬀerent from groups 2, 3,4on all timepoints except at t49 and t56where group 5 issigniﬁcantlydiﬀerent onlyfrom groups 2 and 3.
fGroup 6 is signiﬁcantly diﬀerent from groups 2, 3, 4 on all time points except at t56 where group 5 is signiﬁcantly diﬀerent from 2 and 3 only.
(b)
Time after surgery Gr 1 Gr 2 Gr 3 Gr 4 Gr 5
versus versus versus versus versus
G r o u p s 234 5 6 3456456566
TA Baseline 1.0 1.0 0.685 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0
TA 14 (10)∗ 0.000 0.000 0.000 1.0 1.0 1.0 1.0 0.000 0.000 1.0 0.000 0.000 0.000 0.000 1.0
TA 21 0.000 0.000 0.000 1.0 1.0 0.582 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 1.0
TA 28 0.000 0.000 0.001 1.0 1.0 1.0 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 1.0
TA 35 0.000 0.000 0.000 1.0 1.0 1.0 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 1.0
TA 42 0.000 0.000 0.002 1.0 1.0 1.0 0.000 0.000 0.000 0.000 0.000 0.000 0.001 0.000 1.0
TA 49 0.000 0.000 0.002 1.0 1.0 1.0 0.000 0.000 0.000 0.000 0.000 0.000 0.156 0.027 1.0
TA 56 0.000 0.000 0.018 1.0 1.0 1.0 0.000 0.000 0.000 0.000 0.000 0.000 0.389 0.156 1.0
As a contrast, the TA score for the laminectomy control
animals (Group 1) was 34.5g (SEM 0.26) at day 14. This
two-week time point after surgery (laminectomy or SCI)
was occurring immediately before cell transplants in subsets
of those animals, and all injured animals which were to
receive cell transplants the next day had mean latency scores
not signiﬁcantly diﬀerent from injury-alone rats (Group 2
versus Group 4 [SCI/hNT2.19]: 17.60g), (SEM 0.62), P =
1.0. Similarly, the animals with SCI/hNT2.19 cell grafts and
SCI/hNT2.6 group [17.03g (SEM 0.81)] were not signiﬁ-
cantly diﬀerent compared to either Group 2 (P = 1.0) or
Group 3 (P = 1.0) at this time point.
Laminectomy rats which were to receive cell transplants
the next day [t = 14] (Group 5: SCI/hNT2.19 (34.8g
(SEM 0.17))) and Group 6: SCI/hNT2.6 (35.4g (SEM 0.39))
had mean latency scores not signiﬁcantly diﬀerent from
laminectomy-alone rats (Group 1 [34.5g SEM 0.26]), P =
1.0, respectively. However, 7 days after the hNT2.19 cells
were transplanted near the lumbar spinal cord after SCI
(day 21); the threshold for tactile mechanical sensitivity
(TA) was signiﬁcantly (P<0.000) higher (27.2g; 0.98
(SEM)), compared to both the SCI-alone animals (15.9g;
0.86 (SEM)) and those receiving the nonserotonin hNT2.6
cell transplants (18.1g; 0.91(SEM)). The hNT2.19 implants
resulted in recovery of 78.8% of the laminectomy-alone
value and nearly 30% improvement from day 14 score
immediately before transplant for the graft of hNT2.19 cells
afterSCI.Thus, transplants ofthe nonserotonin hNT2.6cells
had no signiﬁcant eﬀect on the development of allodynia
by SCI at this time point. By 56 days after SCI, when
cell grafts of hNT2.19 had been in place for 6 weeks, the
mean threshold value had signiﬁcantly increased to 32.2g14 Neurology Research International
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Figure 8: Sensory behaviors after severe contusive SCI and followingtransplantofhNT2.19 or hNT2.16 cells in vivo. Rats were injured with
a weight drop device (NYU impactor, 25mm) in a rat model of SCI and chronic behavioral hypersensitivity and motor dysfunction. All
animals in the study received CsA (10mg/kg) 1 day before and for 2wks after the two-week time point (14 days) when some animals were
injected with hNT2.19 or hNT2.6 cells. Animals either received SCI alone, laminectomy alone, or SCI plus hNT2.19 or hNT2.6 cells (106
cells/injection),orlaminectomyplus eitherhNT2.19orhNT2.6cells intothesubarachnoidspace attwoweeks after SCI.Animalswere tested
before the SCI (baseline) and once a week following SCI and treatments for hypersensitivity to tactile (a) or thermal (b) stimuli in hindpaws
below the SCI. All animals were examined for chronic behavioral hypersensitivity in the right and left hindpaws, but since resultant scores
were not signiﬁcantly diﬀerent between hindpaws, data was pooled and averaged. SCI injury negatively aﬀected hindpaw responses. Neither
hindpaw recovers normaltactile or thermal responses after SCI alone orwith transplantofnonserotonergichNT2.6 cells by 56 days after the
severe contusive spinalinjury. Data represent the mean value + SEM (n = 4–9 animalsin each group) at each time point before and 56 days
after SCI. Only the hNT2.19 cell grafts attenuated tactile allodynia (a) and thermal hyperalgesia (b) induced by SCI. Recovery of behaviors
after graft of hNT2.19 cells was near normal at the completion of the experiments.
(SEM 0.47), compared to 17.0g (SEM 0.50), P<0.000,
f o rS C Ia l o n e .A tt h es a m et i m ep o i n t ,5 6d a y s ,t h em e a n
laminectomy threshold value for Group 1 was 34.9g (SEM
0.11); as a comparison the laminectomy/hNT2.19 value
was 34.0g(SEM 0.14). These values were not signiﬁcantly
diﬀerent from each other, P = 1.0.
All animals were tested behaviorally at least two weeks
beforeSCItoestablishbaselinemeasures andbehavioraltest-
ing continuedforabout60daysafterSCIforfoot withdrawal
in response to noxious thermal (heat) stimulation (thermal
hyperalgesia) with a Hargreaves device (Figure 8(b))a s
described in Section 2. In laminectomy control animals
without SCI (Group 1) there were no signiﬁcant deviations
from baseline with the exception of Day 21 and 28 after
laminectomy where withdrawal was slightly but signiﬁcantly
(P<. 05) faster than at baseline. Similarly, in animals
with laminectomy and either hNT2.19 (Group 6) or hNT2.6
transplants (Group 5), no signiﬁcant diﬀerences compared
to baseline values were observed in hindlimb withdrawal
latency to noxious thermal stimulation over the 60-day
period. In SCI animals (Group 2), the mean latency score
was 6.53s (SEM 0.41) at two weeks after SCI (t14). At the
two-week time point, the score for the laminectomy control
(Group 1) animals was 14.2s (SEM 0.26). This two-week
time point after surgery (laminectomy orSCI)wasoccurring
immediately before cells were transplanted in subsets of
those animals. All injured animals which were to receive
cell transplants the next day (Groups 3 and 4) had mean
latency scores of 7.84s (SEM 0.45); Group 4 (SCI/hNT2.19
and Group 3 [SCI/hNT2.6]had latency scoresof 8.17s(SEM
0.26). These were not signiﬁcantly diﬀerent from the latency
scores of injury alone rats (Group 2) 6.53 (0.41 SEM) P =
.19 and P = .90. Laminectomy rats which were to receive
cell transplants the next day (Group 5 [SCI/hNT2.19]: 14.5s
(SEM 0.12) and (Group 6 [SCI/hNT2.6]: 14.4s (SEM 0.17)
had mean latency scores not signiﬁcantly diﬀerent from
laminectomy-alone rats (Group 1 [14.2 SEM 0.26]), P =
1.0. However, 7 days (Time 21) after hNT2.19 cells were
transplanted near the lumbar spinal cord after SCI (Group
4), and the threshold for thermal sensitivity (11.4; SEM
0.39) had improved signiﬁcantly (P<0.000), compared
to both the SCI-alone (7.63 (SEM 0.31) animals and to
those receiving the nonserotonin hNT2.6 (8.46; SEM 0.27)
cell transplants, although the withdrawal latency was still
signiﬁcantly (P<0.000) shorter compared to Group 1
(14.0; SEM 0.11). This represents 81.8% recovery, compared
to laminectomy-alone and greater than 25% improvement
after transplant, compared to day 14, immediately beforeNeurology Research International 15
Table 2: (a) ANOVA showing thermal hyperalgesia thresholds, (b) Post hoc tests Thermal hyperalgesia (Bonferroni corrected P values
shown).
(a)
Time after
contusion
Group 1:
laminectomy
N = 5
Group 2:
contusion
N = 7∗
Group 3:
contusion +
hNT2-6
N = 6∗
Group 4:
contusion +
hNT2-19
N = 7∗
Group 5:
laminectomy +
hNT-19
N = 5
Group 6:
laminectomy +
hNT2-6
N = 7
One way ANOVA
Mean (SEM) Mean (SEM) Mean (SEM) Mean (SEM) Mean (SEM) Mean (SEM) F-statistic, P value
Baseline 14.6 (0.09) 14.7 (0.14) 14.5 (0.18) 14.5 (0.10) 14.3 (0.12) 14.2 (0.17) 1.46, P = .230 (ns)
7 14.2 (0.17)a 7.11 (0.21)b NA NA NA NA 607.0, P<. 000
14 (10)∗ 14.2 (0.26)a 6.53 (0.41)b 8.17 (0.26)c 7.84 (0.45)d 14.5 (0.12)e 14.4 (0.17)f 144.3, P<. 000
21 14.0 (0.11)a 7.63 (0.31)b 8.46 (0.27)c 11.4 (0.39)d 14.7 (0.10)e 14.5 (0.15)f 137.3, P<. 000
28 13.9 (0.13)a 7.36 (0.18)b 7.80 (0.39)c 12.2 (0.26)d 14.2 (0.11)e 14.2 (0.18)f 184.3, P<. 000
35 14.3 (0.12)a 7.54 (0.08)b 8.02 (0.38)c 12.3 (0.28)d 14.6 (0.16)e 14.4 (0.09)f 232.5, P<. 000
42 14.2 (0.10)a 7.26 (0.08)b 7.73 (0.35)c 13.3 (0.40)d 14.1 (0.30)e 14.4 (0.10)f 173.8, P<. 000
49 14.5 (0.20)a 7.56 (0.14)b 7.89 (0.42)c 12.8 (0.29)d 14.4 (0.16)e 14.6 (0.12)f 189.1, P<. 000
56 14.8 (0.11)a 7.50 (0.12)b 7.76 (0.49)c 13.2 (0.49)d 14.6 (0.10)e 14.6 (0.18)f 120.7, P<. 000
∗Time after contusion t14 is 10 days for groups 2, 3, 4 and 14 days for 1, 6, and 7.
Post hoc analyses (Bonferroni):
aGroup 1 is signiﬁcantlydiﬀerent than Groups 2, 3, 4 at all time points except for t42 when it is not signiﬁcantlydiﬀerent from group 4.
bGroup 2 is signiﬁcantlydiﬀe r e n tt h a nG r o u p s1 ,4 ,5 ,6a ta l lt i m ep o i n t se x c e p tf o rt14 when it is not signiﬁcantlydiﬀerent from group 4 but from group 3.
cGroup 3 is signiﬁcantlydiﬀe r e n tt h a nG r o u p s1 ,4 ,5 ,6a ta l lt i m ep o i n t se x c e p tf o rt14 when it is not signiﬁcantly diﬀerent from group 4 but from group 3.
dGroup 4 is signiﬁcantly diﬀerent from all groups on times 21, 28, 35, 49; t14: signiﬁcantly diﬀerent from groups 1, 5, 6; t42: signiﬁcantly diﬀerent from
groups 23; t56: all but 5 and 6.
eGroup 5issigniﬁcantlydiﬀerent fromgroups 2,3,4on alltimepoints exceptat t42andt56,where group 5issigniﬁcantlydiﬀerent onlyfromgroups 2and 3.
fGroup 6 issigniﬁcantlydiﬀerent fromgroups 2, 3,4 on alltimepoints except at t42 and t56 where group 6is signiﬁcantlydiﬀerent from groups 2and 3 only.
(b)
Time after surgery Gr 1 Gr 2 Gr 3 Gr 4 Gr 5
versus versus versus versus versus
G r o u p s 234 5 6 3456456566
TH Baseline 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 0.408 1.0 1.0 1.0 1.0 1.0 1.0
TH 14 (10)∗ 0.000 0.000 0.000 1.0 1.0 0.19 0.90 0.000 0.000 1.0 0.000 0.000 0.000 0.000 1.0
TH 21 0.000 0.000 0.000 1.0 1.0 0.486 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 1.0
TH 28 0.000 0.000 0.001 1.0 1.0 1.0 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 1.0
TH 35 0.000 0.000 0.000 1.0 1.0 1.0 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 1.0
TH 42 0.000 0.000 0.226 1.0 1.0 1.0 0.000 0.000 0.000 0.000 0.000 0.000 0.448 0.051 1.0
TH 49 0.000 0.000 0.000 1.0 1.0 1.0 0.000 0.000 0.000 0.000 0.000 0.000 0.001 0.000 1.0
TH 56 0.000 0.000 0.028 1.0 1.0 1.0 0.000 0.000 0.000 0.000 0.000 0.000 0.111 1.0 1.0
transplant. By 56 days after SCI, when cell grafts of hNT2.19
had been in place for 6 weeks, the mean threshold value
had signiﬁcantly increased to 13.2 (SEM 0.49), which was
signiﬁcantly diﬀerent P<0.000 compared to 7.50s (SEM
0.12), for SCI alone. At the same time point (t56) the mean
laminectomy (Group 1) threshold value was 14.80s (SEM
0.11);thelaminectomy/hNT2.19 (Group6)valuewas14.55s
(SEM 0.10), not signiﬁcantly diﬀerent from each other, P =
1.0. (see Figure 8(b),T a b l e s2(a) and 2(b)).
The responses for the various groups were almost
identical for SCI alone (Group 2) and SCI plus nonserotonin
NT2.6 (Group 3) cells (see Tables 1 and 2,a n dFigure 8).
However, they were signiﬁcantly diﬀerentfrom the responses
obtained from the animals with SCI and NT2.19 cell
implants. Animals in the latter group recovered near normal
sensory responses totactile(Figure 8(a))andthermalstimuli
(Figure 8(b)), representing 92% and 89% percent recovery,
respectively, by 56 days after SCI (6wks after transplant)
after grafting the serotonergic hNT2.19 cells, but not those
animals in the SCI-alone group or those in the hNT2.6 cells
group.
4.3. Motor Behaviors after SCI and Transplant of hNT2.19 or
hNT.6 Cells. Assessment of open-ﬁeld gross motor behavior
using the BBB locomotor scale after SCI (Figure 9 and
Table 3) in the presence or absence of either hNT2.19 of
hNT2.6 cell grafts revealed that SCI alone, using a 25mm
weight drop injury, resulted in a gradual recovery of motor
behavior that reached a plateau at 3-4 weeks following injury
and remained essentially unchanged thereafter to the end of
the experiment, with the best recovery appearing the last
few weeks after SCI. The mean value at 21 days for this16 Neurology Research International
Table 3: ANOVA showingBBB scores.
Time after
contusion
Group 1:
laminectomy
N = 6
Group 2:
contusion
N = 7
Group 3:
contusion +
hNT2-6
N = 6
Group 4:
contusion +
hNT2-19
N = 9
Group 5:
laminectomy +
hNT-19
N = 5
Group 6:
laminectomy
+hNT2-6
N = 7
One way ANOVA
Mean (SEM) Mean (SEM) Mean (SEM) Mean (SEM) Mean (SEM) Mean (SEM) F-statistic,
P value
Baseline 21.0 (0.00) 21.0 (0.00) 21.0 (0.00) 21.0 (0.00) 21.0 (0.00) 21.0 (0.00) NA
Day 1 16.67 (3.28) 0.29 (0.10) 0.58 (0.58) 0.67 (0.32) 21.0 (0.00) 21.0 (0.00) 73.0; P<. 000
Week 1 17.25 (2.71) 4.36 (1.39) 3.67 (1.41) 2.83 (0.80) 21.0 (0.00) 21.0 (0.00) 44.6; P<. 000
Week 2 17.75 (2.78) 7.29 (1.37) 6.00 (1.53) 5.89 (1.07) 21.0 (0.00) 21.0 (0.00) 27.4; P<. 000
Week 3 17.92 (2.62) 7.71 (1.15) 6.08 (1.58) 7.28 (1.05) 20.4 (1.34) 20.5 (0.50) 24.9; P<. 000
Week 4 18.83 (2.17) 9.29 (0.65) 7.75 (1.45) 7.17 (1.41) 21.0 (0.00) 19.8 (0.99) 23.6; P<. 000
Week 5 18.83 (2.17) 9.29 (0.64) 8.17 (1.45) 7.28 (1.50) 21.0 (0.00) 20.6 (0.43) 25.1; P<. 000
Week 6 18.83 (2.17) 9.57 (0.57) 8.92 (0.85) 7.67 (1.53) 21.0 (0.00) 20.6 (0.43) 25.9; P<. 000
Week 7 18.92 (2.08) 9.86 (0.46) 8.75 (1.03) 7.28 (1.46) 21.0 (0.00) 21.0 (0.00) 30.3; P<. 000
Week 8 18.92 (2.08) 9.86 (0.46) 8.50 (1.33) 7.83 (1.45) 21.0 (0.00) 21.0 (0.00) 27.3; P<. 000
Post hoc analyses (Bonferroni):
Group 1 is signiﬁcantlydiﬀerent than Groups 2, 3, 4 on all time points.
Group 2 is signiﬁcantlydiﬀerent than Groups 1, 5, 6 on all time points.
Group 3 is signiﬁcantlydiﬀerent than Groups 1, 5, 6 at all time points.
Group 4 is signiﬁcantlydiﬀerent than Groups 1, 5, 6 at all time points.
Group 5 is signiﬁcantlydiﬀerent than groups 2, 3, 4 on all time points.
Group 6 is signiﬁcantlydiﬀerent than groups 2, 3, 4 on all time points.
group (Group 2, SCI only, n = 7) was 7.71 SEM (1.15) and
9.86 SEM (0.46) at 56 days. The decreased BBB scores after
SCI were signiﬁcantly (P<0.000) lower than baseline
for all time points. The results for the animals with SCI
plus nonserotonin hNT2.6 grafts (Group 3) showed similar
decreases that were not signiﬁcantly diﬀerent from the
animals with contusiononly.The BBBscoresfortheSCIplus
hNT2.19 grafts (Group 4) were also nearly identical, with no
signiﬁcant statistical diﬀerencefrom the BBBscores from the
SCI plus hNT2.6 or SCI alone animals during all 56 days.
Similar comparisons were made between all groups where
the ANOVA (Table 3)s h o w e do v e r a l ls i g n i ﬁ c a n td i ﬀerences
between groups at all time points except for the baseline
comparison between the laminectomy-alone group (Group
1, n = 5) and neither the laminectomy plus hNT2.6 (Group
6, n = 7) or laminectomy plus hNT2.19 (Group 5, n = 5)
cellgraftgroupsshowed signiﬁcant diﬀerencesbetweenthese
groupsonanyofthetimepoints.TheaverageBBBscoreat21
days for this group (Group 1, laminectomy only) was 17.92
SEM (2.62) and 18.92 (2.08) at the experiment’s end (56
days). These data suggest that subarachnoid grafts of either
hNT2.19 or hNT2.6 cells had no signiﬁcant eﬀect on the rate
or magnitude of limited motor recovery when measured by
open-ﬁeld behaviors for 56 days after severe contusive SCI
(see Figure 9 and Table 3).
Severe contusive SCI causes a permanent increase in
gridwalk footfall errors, decrease in stride length, decrease
in base of support, and change in degree of foot rotation
in hindlimbs by eight weeks after injury. Initially before
injury and at the end of the experiment, all six groups
of rats were assessed for footfall error with gridwalk
error testing (Figure 10(a)) and footprint analysis of stride
length (Figure 10(b)), base of support (Figure 10(c)), and
degree of foot rotation (Figure 10(d);d a y5 6 ) .C o m p a r i s o n s
between groups, including post hoc tests, showed no sig-
niﬁcant improvement with the addition of SCI/hNT2.19 or
SCI/hT2.6 grafts in gridwalk errors, stride length, base of
support, or foot rotation following SCI. The only signiﬁcant
diﬀerences observed were between injured and uninjured
rats, Groups 2, 3, 4 and Groups 1, 5, 6, respectively, in
gridwalk errors and stride length (F = 30.913, P<0.000,
gridwalk; F = 3.102, P<. 05, stride length; F = 1.159, P>
.05, base of support; and F = 0.794, P>. 05, foot rotation).
Footfall error (a) in the SCI rats (Group 2) had a mean value
of 7.625 errors SEM (0.449, n = 8), while the SCI/hNT2.19
(Group 4) or SCI/hNT2.6 (Group 3) rats had mean values
of 8.333 errors SEM (1.522, n = 7) and 10.933 errors SEM
(0.985, n = 5), respectively. The laminectomy (Group 1) or
laminectomy plus hNT2.19 (Group 5) or hNT2.6 Group 6)
rats had mean values of 0.1 errors SEM (0.1, n = 5), 0.533
errors SEM (0.17, n = 7) and 0.667 errors SEM (0.291,
n = 7), respectively. Baseline values (before injury) were
0.305errorsSEM(0.043,n = 47).Stridelength(b)intheSCI
rats (Group 2) had a mean value of 12.974cm SEM (0.808,
n = 5), while the SCI/hNT2.19 (Group 4) or SCI/hNT2.6
(Group 3) rats had mean values of 11.15cm SEM (0.05,
n = 2) and 12.617cm SEM (0.835, n = 3), respectively.
The laminectomy (Group 1) or laminectomy plus hNT2.19
(Group5)orhNT2.6(Group6)hadmeanvaluesof14.73cm
SEM (0.404, n = 5), 11.15cm SEM (0.639 n = 5) and
12.341cm SEM (0.436, n = 7), respectively, while the
SCI/hNT2.19 (Group 4) or SCI/hNT2.6 (Group 3) rats
had mean values of 11.15cm SEM (0.05, n = 2), and
12.617cm SEM (0.835, n = 3), respectively. Baseline valuesNeurology Research International 17
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Figure 9: Open-ﬁeld motor behaviors (BBB) and graft of hNT2.19
or hNT2.6 cells in severe contusive SCI. Gross open-ﬁeld motor
behavioralresults showgradual recovery ofmotor scores beginning
at 1 week after SCI, with no additional recovery with the addition
of hNT2.19 or hNT2.6 grafts. Data represent the mean value +
SEM (n>6 animals in each group) at each time point for 56
days after SCI. BBB scores did not improve over the natural history
of recovery after SCI, when either cell line was grafted into the
subarachnoid space. Laminectomy alone had no eﬀect on normal
BBB scores, and addition of hNT2.19 or hNT2.6 grafted cells to
laminectomy animals was not diﬀerent from laminectomy alone.
The hNT2.19 cell therapy, when cells are transplanted into the
lumbar subarachnoid space, has no eﬀect on open-ﬁeld motor
behaviors, with or without severe contusive SCI.
for uninjured rats were 14.757cm SEM (0.269, n = 67). Base
of support (c) in the SCI (Group 2) rats had a mean value
of 2.996cm SEM (0.571, n = 5), while the SCI/hNT2.19
(Group 4) or SCI/hNT2.6 (Group 3) rats had mean values of
2.85cmSEM(0.45,n = 2)and 3.513cmSEM(0.146,n = 3),
respectively. The laminectomy (Group 1) or laminectomy
plushNT2.19(Group 5) orhNT2.6(Group 6)ratshad mean
valuesof3.766cmSEM(0.257,n = 5),2.924cmSEM(0.125,
n = 5), and 3.339cm SEM (0.168, n = 7), respectively.
Baseline values for base of support (uninjured) rats were
3.272cm SEM (0.169, n = 67). Foot rotation (d) in the SCI
(Group 2) rats had a mean value of 16.125◦ SEM (3.708, n =
4),while the SCI/hNT2.19(Group 4)or SCI/hNT2.6(Group
3) rats had mean values of 10.55◦ SEM (2.25, n = 2) and
n.d. (no data), respectively. The laminectomy (Group 1) or
laminectomy plus hNT2.19 (Group 5) or hNT2.6 (Group 6)
rats had mean values of 15.82◦ SEM (1.015, n = 5), 14.534◦
SEM (1,428, n = 5), and 13.92◦ SEM (1.219, n = 7), respec-
tively. Baseline values for foot rotation (uninjured) rats was
11.804◦ SEM (0.372, n = 67). Inconsistencies in measures,
numbers, and missing data, between injured and uninjured
rats are related to the severity of injury (25mm weight drop)
causing animals to move poorly by 8 weeks after SCI, even
though they have survived SCI and transplant surgeries.
5.Discussion
The teratocarcinoma human NT2 (hNT2) parental cell line
was the source of the hNT2.19 cell line derived from the
embryonic carcinoma (EC) cell type, after diﬀerentiation
in response to retinoic acid (RA). The NT2 parent cell
line has been used for a great variety of studies since its
initial description in 1984 [29, 34]. A derivative of the
original polyclonal TERA-2 EC cell line, the NT2/D1 line
(NT2), is cells with the phenotypic properties of neurons
after diﬀerentiation, including the expression of neuroﬁl-
ament proteins [50]. This resultant, exclusively neuronal,
phenotype with RA treatment has remained a hallmark
of this human cell line, unlike other cells of EC origin
[51]. The RA-diﬀerentiated neurons, called NT2-N cells, are
from a committed neuronal cell precursor as determined
by lineage analysis [28]. They are similar to developing
human spinal cord neurons, reminiscent ofterminally diﬀer-
entiated postmitotic neurons. To achieve pure populations
of neurons, rapid methods have been developed [52]t h a t
include treatment of RA-induced NT2 cultures with mitotic
inhibitors toenrich forneurons thatexpress typicalneuronal
markers [53] with a stable polarized phenotype [52]o f
central,notperipheralnervoussystemneurons.Afewstudies
[54] describe a variety of neurotransmitter or neuropeptide
phenotypes expressed by NT2-N neurons after 2–4 weeks of
diﬀe r e n t i a t i o ni nv i t r o .T h ec o m m o np h e n o t y p e s ,i n c l u d e
5HT-expressing NT2 cells, range from about2% [32]to 30%
[54], depending on the diﬀerentiation procedures. Further
increasing the proportion of 5HT producing neurons seems
to require particular diﬀerentiation protocols involving the
timed application of various growth factors [55], methods
not used in the current subcloning of the hNT2.19 cell
line. Our diﬀerentiation method is similar to that of the
Guillemain study [54], which provides about 30% 5HT-
containing neurons. This explains the relative ease of ﬁnding
a 5HT-subclone, such as the hNT.19 cell line (see Section 2).
A similarly subcloned NT2-derived GABA cell line such as
our previously described hNT2.17 cell line, also used in SCI-
studies [18], expresses the inhibitory GABA neurotransmit-
ter and simultaneously coexpresses other neurotransmitters
such as met-enkephalin or neuropeptide Y [18]. However,
thehNT2.19celllinedoesnot,inourhands, co-expressother
neurotransmitter markers, such as tyrosine hydroxylase
(TH), choline acetyltransferase (ChAT), neuropeptides such
as calcitonin gene-related peptide (CGRP), the leu- or met-
enkephalins, or neuropeptide Y (NPY). This observation
suggests that it is the 5HT secreted by diﬀerentiated grafted
cells that is the active, antinociceptive agent in this study.
Thus, when the hNT2.19 is transplanted in vivo, the grafts
apparently retain their 5HT-phenotype. Interestingly, when
the parental NT2 parent cell line (which is really a cell
population, rather than a phenotype-restricted cell line) is
transplanted, a GABA phenotype is favored in vivo [56],
but many other phenotypes are possible [57]. Even though
multipotentiality of phenotype expression might be an18 Neurology Research International
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Figure 10: Gridwalk errors/footprint analysis and graft of hNT2.19 or hNT2.6 cells in severe contusive SCI. Gridwalk errors (a), stride
length (b), base of support (c), and foot rotation (d) before and at the end of the experiment (day 56) after SCI or laminectomy, with or
without transplant of hNT2.19 or hNT2.6 cells at 2wks after injury. Data show no signiﬁcant recovery of gridwalk errors, stride length,
base of support, or foot rotation with the addition of graft of either cell line, compared to SCI alone. Data represent the mean value + SEM
(n = 5–8 animals in each group). Laminectomy alone or laminectomy plus either cell line graft had no eﬀect on gridwalk error or footprint
scores.
advantageinaclinicalusewhere thetherapeuticmechanism-
of-action is unknown (i.e., transplant of NT2-N neurons
for stroke [31]), a single, more pure phenotype, such as
that for 5HT, could be preferable for use in conditions such
as neuropathic pain or motor dysfunction following SCI.
Graft of 5HT-secreting cells (using a rat cell line) near the
spinal cord has been demonstrated to attenuate neuropathic
pain after SCI by restoring spinal 5HT and upregulating
spinal BDNF, and downregulating the 5HT transporter [8],
but eﬀects on the sensory system require a subarachnoid
graft location [33], since apparently, in those studies, an
intralesion graft site helps restore motor function. We have
seen similar results with the use of intraspinal hNT2.19
grafts and the severe contusive SCI model [23]. This “proof-
of-concept” and feasibility study makes it clear that graft
location for cell therapy approaches in SCI and recovery-
of-function should be carefully considered in any transplant
strategy, and pain and motor dysfunction might require
diﬀerent graft locations.
Using the rapid aggregation method [35]t od i ﬀerentiate
single-cell clones isolated from the NT2 undiﬀerentiated cell
line, we were able to identify a number of 5HT-staining
cell lines. We chose the hNT2.19 cell line based on its
homogeneous morphology and ease of proliferation and
diﬀerentiation in vitro. Early in the diﬀerentiation process,
the hNT2.19 cells have multiple neurite extensions (stainedNeurology Research International 19
for the neuroﬁlament proteins) with medium- to large-size
cell bodies, where both cell compartments stain brightly
for 5HT. Longer diﬀerentiation on the laminin and poly-
L-lysine substrate causes them to aggregate into balls, with
multiple growing extensions, much like the NT2-N parent
cells [28, 54]. They can be lifted and replated without any
apparent changes, can be frozen and restarted, and have
been maintained without cell division in vitro for greater
than 7 weeks. In light of their apparent 5HT phenotype,
they consistently maintain features of homogeneous cells:
diﬀerentiated cells release synthesized 5HT under basal and
stimulated in vitro conditions, and apparently not any
norepinephrine, which might also be expected to serve as an
antinociceptive agent [58].
In spite of the fact that most people who have sus-
tained an SCI develop persistent pain [59, 60], which has
profound impact on activities [61] and quality of life after
SCI [62, 63], until recently little was known about the
mechanisms responsible for this condition. Althoughpain of
musculoskeletal, radicular, visceral, and psychogenic origins
play a signiﬁcant role in the clinical sequelae of spinal
injury, central dysesthetic pain is the most disabling and
challenging of all sensory complications associated with
SCI [64]. While some SCI pain syndromes may respond
to therapeutic interventions [65], central neuropathic pain
usually fail to respond to any eﬀorts including systemic
and local pharmacology [66], neuroaugmentative and neu-
rodestructive approaches [67]. Alteration of the endogenous
spinal 5HT system after spinal cord injury (SCI) plays a
potential major role in the induction and maintenance of
chronic pain in humans. Supraspinal inhibitory pathways
that project to the dorsal horn include those that supply the
monamines,serotonin(5HT)norepinephrineanddopamine
[27, 68–71]. Of these, 5HT is one of the best studied
neurotransmitters in SCI [72]. Descending serotonergic
pathways originate in brainstem raphe nuclei and terminate
in the superﬁcial dorsal and ventral horns of the cord
[73, 74], providing excitatory drive to inhibitory systems.
Evidence supporting a role for 5HT in antinociception [75–
77] is based on its anatomical location, the behavioral eﬀects
of intrathecal serotonergic drugs [77–79], and inhibition
of spinothalamic tract cells involved in pain transmission
[80]. Loss of 5HT acutely after SCI caudal to an injury
site is a consistent report [1]i nav a r i e t yo fS C Im o d e l s
including deaﬀerentation [3], spinal hemisection [2, 9], and
more recently, clip-compression injuries of the cord [81].
T h i sl o s so f5 H Ta f t e rS C Ih a sb e e nu s e da sa ni n d i c a t o ro f
injury severity [82]. After spinal hemisection, with injury-
induced tactile allodynia and thermal hyperalgesia, animals
develop hypersensitivity to lower doses of intrathecal 5HT
for antinociception, related to speciﬁc 5HT1A and 5HT3
receptors in the dorsal horn [4]. Grafts of cells that release
5HT into the intrathecal space following dorsal hemisection
restore spinal 5HT in the dorsal horn [8], increasing 5HT in
theCSF,andcorrectmembranehyperexcitabilityandpheno-
type shifts of dorsal horn neurons [9] associated with tactile
allodynia and thermal hyperalgesia following SCI. These
same 5HT rat cell line grafts are not antinociceptive when
placed within the cord, rather than a subarachnoid location,
in the same injury paradigm [33], arguing for a focal
application of serotonin to/near the dorsal horn (e.g., the
subarachnoid space), without further disturbance to the
cord, that is required for an only-antinociceptive strategy
with a cell therapy approach.
There is also a signiﬁcant role for serotonin to enhance
motor recovery of function after SCI [72], based on its
eﬀects on ventral motor neurons. Endogenous and exoge-
nously applied serotonin modulates the motor system and
stimulates motor recovery after SCI [83], with 5HT agonist
applicationseentodirectlydepolarizeα-motorneurons[84].
The central patterngenerator(s), the local circuitry responsi-
bleforrhythmic controloflimbmovements,ismodulatedby
descending serotonergic inputs [85], where the 5HT spinal
innervation is eliminated below the level of SCI following
injury. Following spinal transection, rhythmic locomotor
function and increased responsiveness to reﬂex testing can
be restored by transplant of embryonic serotonergic raphe
cells [86], presumably by replacement of synaptic con-
nections to motor neurons and release of 5HT in the
immediate environment [87]. Our earlier published data
indicates that, using grafts of rat 5HT cells derived from
an immortalized 5HT cell line [5], locomotor function can
only be improved after SCI when grafts are placed within
the cord; the same grafts eﬀective for nociception are only
eﬀective when placed in the subarachnoid space [33], by
attenuating the neuronal hyperexcitability induced by SCI in
the dorsal horn [9]. The eﬀects on motor neurons by 5HT-
secreting intraspinal grafts are presumably by increasing
excitability of host neurons through increases in amplitude
of monosynaptic reﬂexes in the central pattern generator
circuitry [88], given the excitatory role of 5HT in the ventral
horn [83], as opposed to the indirect inhibitory role for
5HT in the dorsal sensory horn system [89]. Agonists for
5HTmayfacilitate,ratherthandirectlygenerate,stepping,by
enabling the spinal cord neural circuitry to process speciﬁc
patterns of sensory information associated with weight-
bearing stepping, an eﬀect that enhances rehabilitative
training [83]. When hNT2.19 are grafted intraspinally, near
the contusion site, motor behaviors, such as improvement in
open-ﬁeldmovements,ﬁnemotormovements,footrotation,
and reduced footfall errors, are improved. Interestingly,
these improvements are enhanced when a rehabilitation-
like treatment, environmental enrichment, is added to the
transplant paradigm [23]. The current study adds further
evidence to clarify how human 5HT-secreting neuronal
grafts might diﬀerently aﬀect sensory and motor recovery
after SCI based on graft location, since motor recovery is not
aﬀected by subarachnoid grafts of 5HT-secreting cells.
With a likely serotonin-based mechanism to explain the
varying eﬀects of the diﬀerent graft location(s) for the
hNT2.19 cell line, it is important to mention how an
external source of 5HT might diﬀuse in the spinal cord
environment. And since the hNT2.19 grafts survive well
in the subarachnoid space and continue to synthesize the
5HT neurotransmitter in situ, it can be presumed that they
functionascellularminipumpstocontinuouslyprovide5HT
to the immediate environment throughout their survival.
Serotonin is known to rapidly degrade metabolically, so a20 Neurology Research International
cell-generating continual source might be thebest method to
provide authentic 5HT, rather than say, a surgical minipump
device, as is commonly done in some pain management
approaches. But 5HT replacement to or near the spinal cord
(such as the dorsal horn sensory system) must take into
account the poor diﬀusion properties of 5HT in the spinal
cord [90], where a negative relation between initial injection
concentration of 5HT and detection of 5HT with distance
from injection site, after intraspinal injection, was seen.
With lumbosacral surface applications of 5HT, the amount
of 5HT crossing the arachnoid and pia membranes and
entering the spinal cord after superfusion was signiﬁcantly
less than that observed with diﬀusion of 5HT through spinal
gray matter after intraspinal microinjection, so that only a
relatively low percentage of the applied 5HT is delivered
within the cord. The authors report that relatively small
amounts of 5HT enter the spinal cord gray matter, with
<0.8% of the bath solution concentration being detected in
the superﬁcial dorsal horn (within 400μmo ft h es u r f a c e ) .
Even smaller amounts of 5HT reach the intermediate zone
and ventral horn. But unlike cell-based sources for 5HT,
which continuously secrete and renew the neurotransmitter,
a single application of 5HT to the dorsal horn could not
be expected to be as eﬀective as a treatment for behav-
ioral hypersensitivity. Whatever barriers to rapid and long-
distance diﬀusion of 5HT exist in the cord, and considering
that 5HT entering the dorsal cord would be in much lower
concentrations (along a concentration gradient) compared
to the same concentration released from a ventral motor cell
graft, it is logical to expect a dorsal source not likely to be
useful to a ventral motor functionality. The results of the
current study support that conclusion.
Important in the consideration of any clinical use of
cell line grafts, even those of stem-cell origin [91], the
diﬀerentiated hNT2.19 cells do not demonstrate any features
of a tumor cell line, since they do not express tumor-
related genes or is able to incorporate a BrdU signal with
diﬀerentiation, much like its NT2-N parent [45]. Tumor
proteins are abundant in the proliferating hNT2.19 cells,
suggesting that only a diﬀerentiated hNT2.19 cell would be
safe to transplant in vivo. In previous studies [92], we have
described the transplant and use of diﬀerentiated hNT2 cell
lines to treat pain and motor dysfunction after SCI in rats.
Grafting well-diﬀerentiated hNT2.19 cells into the CNS does
not form tumors in rats (in over 100 animals grafted), and
their use supports such a contention.
There is considerable evidence for the use of cell therapy,
where graftsfunction ascellularminipumps in thesubarach-
noid space in various models of nerve injury [93]a n ds p i n a l
cord injury [94]. For such therapies to reach clinical usage,
a number of issues will need to be considered. A typical
beneﬁt of such grafts would be the delivery of therapeutic
agents, such as neurotransmitters, with a biological half-life
too short to be delivered by any other means, (such as the
commonly used baclofen mechanical pump used for SCI
spasticity) [95–97]. Direct delivery of an endogenous dorsal
hornmolecule,suchasbycelltherapy,isapotentialapproach
that we have investigated in the present study. To directly or
indirectly supply 5HT or other labile antinociceptive agents
via cell therapy is a developing idea in preclinical studies
[98].The next step towards thedevelopmentof5HTdelivery
interventions in human neuropathic pain would include the
creation of a human source of expandable 5HT-supplying
cells.
Additionally, given the serious outcomes of long-term
immunosuppression required in human cell therapy trans-
plants, the issues regarding any required immunosuppres-
sion regime for spinal intrathecal cell transplants are com-
plex. Here we have use of a minimal course of CSA (2 weeks
following cell transplant) to ensure a modest graft survival
in the xenograft model (human to rat). Our earlier studies
indicate that at least some time course of CSA is required
for adequategraft survival and therapeuticeﬀectiveness[99],
representing a minimal use of immunosuppression with
a subarachnoid graft in humans. In this earlier study, a
number of trends were seen related to immunosuppression
regimen: (1) a minimal course of immunosuppression with
CsA, about 1 to 2 weeks after transplants, is required;
(2) this minimal CsA course ensures optimal eﬃcacy in
reversal of the behavioral hypersensitivity associated with
SCI pain; (3) less than minimal immunosuppression (1 day)
only provides minimal eﬃcacy; (4) longer than the optimal
time course of CsA does not improve eﬃcacy signiﬁcantly.
In this study with the similar hNT2.17 grafted cell line,
we examined immunostained sections at the end of the
experiment and although reliable quantiﬁcation of grafts is
almost impossible, there were clearly fewer surviving grafts
with less than 2 weeks of CsA. A “critical” number of
functioning grafted cells could inﬂuence or permanently
aﬀect the therapeutic sensory eﬀects. Precise answers as to
possiblemechanisms arediﬃcult,butonevalueofpreclinical
studies is that they can reveal such diﬀerences in outcomes
with manipulation of likely clinical variables.
However, it is also important to mention the typical
drawbacks that cell therapy for SCI pain might include:
(1) possible limits to the achievable levels of a given agent
that can be delivered by the cells; (2) possible delivery of a
multitude of substances in addition to those of therapeutic
interest, many of which cannot be completely deﬁned; (3)
dependence on the survival of implanted cells, which may
be limited by immunologic factors, nutrient, and oxygen
supply, and so forth. Some of these complicating issues
for subarachnoid grafts are highly relevant for the future
development of potentially beneﬁcial interventions and for
the interpretation of the present results including the initial
description of the use of a human neuronal hNT2.19
serotonergic cell line graft in an animal model of SCI pain.
Hopefully, they will be addressed in later studies with the
NT2-derived cell lines.
In summary, cellular therapy for neuropathic pain after
severecontusiveSCIisamethodtochronicallydeliverpoten-
tially antinociceptive molecules, such as 5HT, to the local
CNS environment of the spinal cord where the messages for
the induction and establishment of chronic pain are initially
translated to supraspinal pain centers. Intrathecal trans-
plantation of the hNT2.19 cell line has proven to potently
reverse SCI-induced behavioral hypersensitivity (pain-like)
behaviors. Genetically modiﬁed cell lines can provide aNeurology Research International 21
virtually inﬁnite supply of an easily characterized biologic
tool to provide analgesia. Such cellular minipumps can be
developedasareﬁned adjuncttothecurrentlyusedtherapies
for the management of painful neuropathies.
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